Attilio Bondanza, MD, PhD, from the San Raffaele Scientific Institute, Milano, Italy talks to us about a Phase I/II trial, which will take place in the future, investigating the effectiveness of using CAR T-cells to treat refractory acute myeloid leukemia, sponsored by the biotechnology company, MolMed. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.